The Institut national d’excellence en santé et en services sociaux (INESSS) released its recommendation on funding Hemlibra (emicizumab) for the treatment of severe hemophilia A...
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without...
NOVEMBER 5-7 Many innovative and curative therapies are coming to market for rare blood disorders, but will they be available to Canadian patients? What is...
The World Federation of Hemophilia (WFH) has published the 3rd Edition of the Guidelines for the Management of Hemophilia, replacing the 2nd Edition published in...
The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the...